FindTrial
Sign In

Tumor markers combine with LDCT in diagnosis of lung cancer in baseline survey in Beijing

Tumor markers combine with LDCT in diagnosis of lung cancer in baseline survey in Beijing

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024251
Enrollment
Unknown
Registered
2019-07-03
Start date
2015-05-06
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Case series:Nil

Sponsors

Beijing Chest Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 40-74 years or older; 2. The Smoking cessation of the individual < 15 years; 3. With risk factors (radon exposure / occupation exposure / history / family history of malignant tumor / lung cancer lung disease history (COPD, pulmonary fibrosis) / secondhand smoke exposure); 4. The participants signed the informed consent; 5. The subject has the ability to accept the inspection (such as: supine hand on her head);

Exclusion criteria

Exclusion criteria: 1. Appear to stimulate cough, sputum with blood, chest pain, unexplained weight loss, such as lung cancer related symptoms. 2. The important organs such as heart, liver and kidney have obvious damage or severe dysfunction. 3. The pregnant women. 4. A metal stent or internal fixation in the back.

Design outcomes

Primary

MeasureTime frame
lung LDCT and lung cancer serum tumor markers;—

Contacts

Public ContactXu Shaofa

Beijing Chest Hospital, Capital Medical University

kyb6295@sina.com+86 010-89509188

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026